INTRODUCTION. J. Radiat. Res., 53, (2012)
|
|
- Osborn Todd
- 5 years ago
- Views:
Transcription
1 J. Radiat. Res., 53, (2012) The Effects of Two HDR Brachytherapy Schedules in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiation: A Study from Chiang Mai, Thailand Ekkasit THARAVICHITKUL 1 *, Pitchayaponne KLUNKIN 1, Vicharn LORVIDHAYA 1, Vimol SUKTHOMYA 1, Somvilai CHAKRABHANDU 1, Nantaka PUKANHAPHAN 1, Imjai CHITAPANARUX 1 and Razvan GALALAE 2 Cervix carcinoma/hdr/brachytherapy/schedules. Efficacy of different schedules of HDR brachytherapy in concurrent chemoradiotherapy was evaluated. The study compared the effectiveness of the two HDR brachytherapy schedules which have the same Biological Effective Dose (BED) in locally advanced cervical carcinoma that was treated with concurrent chemoradiotherapy. Included in the study were 377 randomly selected patients with advanced carcinoma of the cervix uteri who were treated during the period Patients were divided into : 7.2 Gy 3 fractions and : 6 Gy 4 fractions. With a median follow-up time of 35 months, local control, disease-free survival and overall survival rates were 80.8%, 63.4%, 98.8% in group I and 86.7%, 63.8%, 97.3% in group II, respectively. There was no statistical significance in terms of local control, disease-free survival, overall survival and complication rates between the two treatment schedules which could be observed. Seven patients in group I developed acute grade 2 4 GI toxicities and two patients in group II. In GU toxicities, there were three patients in group I and three patients in group II who developed grade 2 4 toxicities. In late toxicity, no patient developed grade 3 4 GU toxicities in group I while two patients developed grade 3 4 GU toxicities in group II. In GI toxicities, there were five and six patients in group I and group II, respectively, who developed grade 3 4 severity. Both HDR schedules seem to be safe and effective for the treatment of locally advanced cervical cancer. INTRODUCTION Radiotherapeutic treatment of cervical cancer has mainly consisted of External Beam Radiotherapy (EBRT) and Intracavitary Brachytherapy (ICBT). The goal of brachytherapy was to augment the dose of a paracentral point to the dose of Gy. 1) Doses of ICBT were still controversial according to institutional experience but maintained the principles of the International Commission of Radiological Units (ICRU). 2) In ICRU #38, the methods of determining the measurement of bladder and rectal dose points were *Corresponding author: Phone: , Fax: +66/ , paan_31@hotmail.com 1 The Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2 Paul Schrer Institute, Zurich/Villingen, Switzerland and Medical Faculty, Christian- Albrechts-University of Kiel, Germany. Competing interests: The authors declare that they have no competing interests. doi: /jrr identified and the limitations of the dosage at these points noted. High-Dose-Rate (HDR) brachytherapy began in 1958 and has become highly developed during the past 30 years. Iridium-192 (Ir-192) usage was developed utilizing small units which could be applied in many techniques and sites of treatment. The advantages of HDR were rigid immobilization, outpatient treatment, patient convenience, and potential cost savings. 3) In carcinoma of cervix uteri, ICBT with HDR brachytherapy has been administered for many years. The confirmation of meta-analysis showed that there was no difference in efficacies and toxicities between LDR and HDR. 4) Although the usage of HDR brachytherapy in cervical cancer nowadays is agreed without question, the optimal dosage schedule is still controversial. The practical use of HDR brachytherapy varies according to the experiences of individual institutions. The American Brachytherapy Society (ABS) published a recommended dosage schedule of ICBT in cervical cancer in ) The recommended dosage of Gy in 4 6 fractions combined with EBRT Gy was considered acceptable. From the guidelines of the Japan Society of Gynecologic Oncology, the Japanese standard schedule (with the dose of Gy in 3 4 fractions
2 282 E. Tharavichitkul et al. combined with EBRT Gy) has a lower total radiation dose compared with those in the United States. 6) With the standard dose guidelines, the Biological Effective Dose (BED) at point A (α/β = 10) was Gy 10 in ABS recommendations and Gy 10 in the Japanese schedule. So, the optimal HDR-fractionation schedule for the treatment of cervical cancer remained under debate. Various fractionation schemes have been used experimentally in search of the optimal technique. 7) Presently, completed data has confirmed that the results of combined modality therapy (especially with a platinum-containing regimen) can lead to a prolonged time before disease recurrence and an increase in overall survival in locally advanced cervical cancer. 8 10) However, little comparative study between HDR dose schedules has been performed in locally advanced cervical cancer treated with concurrent chemoradiotherapy. This study was performed to evaluate the efficacy of a different schedule of HDR brachytherapy in concurrent chemoradiotherapy. Two HDR brachytherapy schedules were compared utilizing the same Biological Effective Dose (BED) to point A (α/β = 10) for locally advanced cervical carcinoma treated with concurrent chemoradiotherapy. MATERIALS AND METHODS Patient characteristics After approval from the ethics committee, patients with locally advanced carcinoma of the cervix uteri who were treated from 2004 to 2006 were included in the study. All patients had the following characteristics: stage IIB-IVA by FIGO staging, ages years, histology proven carcinoma of cervix uteri, Estern Cooperative Oncology Group (ECOG) performance status scale 0 1, no uncontrolled medical conditions, no previous pelvic surgery or irradiation and had signed the consent form for treatment protocol. Patients who had stage IVB (metastatic disease), allergy were excluded from the study due to their different management. Radiation techniques In External Beam Radiotherapy (EBRT), 6 10 MV photons by PRIMUS linear accelerators were used to treat the whole pelvis. The daily fraction of 2 Gy, five days per week was used to a dose of 50 Gy. Central shielding was applied after 40 Gy regardless of stage. Parametrial boost was used to build up the dose of parametrium to 56 Gy. All patients were treated with concurrent chemoradiotherapy with cisplatin (40 mg/m2 weekly, totally 6 cycles) or mitomycin-c (10 mg/m2 wk 1 and wk 6). The first ICBT was started at the fourth week of radiation therapy. The Fletcher-Suit applicator (Asia-Pacific version) was used in this treatment. In cases of extensive vaginal involvement, intra-vaginal cylinders were used in tandem to treat the primary lesion and vaginal extension. Patients were prospectively randomized into two treatment schedules as follows: : Gy : 4 6 Gy Application of ICBT was performed on an outpatient basis with non-narcotic analgesics. For ICBT simulation, orthogonal films of antero-posterior and lateral views were taken with the applicators inserted, and the position of point A, bladder and rectal points were defined according to the Manchester method and ICRU 38 recommendations. 2) The Linear Quadratic equation was used to calculate the dose to point A which can be calculated as in the following: Biologically effective dose (BED) to the point A (α/β = 10) BED = D (1 + d/α/β) For whole pelvis RT, the BED 10 was 40(1 + 2/10) = 48 Gy 10. For ICBT group I (21.6 Gy/3 Fr), the BED 10 was 21.6( /10) = 37.2 Gy 10. For ICBT group II (24 Gy/4 Fr), the BED 10 was 24(1 + 6/10) = 38.4 Gy 10. So the total BED 10 of was 85.2 Gy 10 and total BED 10 of group II was = 86.4 Gy 10. Evaluation During treatment, patients were appointed to visit the physician to evaluate the toxicities according to the National Cancer Institute; Common Terminology Criteria of adverse event (CTCAE) version ) After the treatment was completed, patients were appointed to visit for a vaginal examination (PV exam) in a follow-up program. A vaginal examination was performed to evaluate the disease status according to the World Health Organization (WHO) criteria. 12) Late toxicities were evaluated according to the Radiation Therapy Oncology Group/ European Organization of Research and Treatment of Cancer (RTOG/EORTC) late toxicity criteria. 13) Statistical analysis All data were inputed to SPSS software version Tumor response rate, local control, disease-free survival, and Overall survival rates were evaluated between the two groups by the chi-square test. Survival data were calculated by the Kaplan-Meier method and log-rank test to identify any statistical significance between the two groups. 14,15) RESULTS Patient data A total of 377 patients were included in this study. Seventeen patients were excluded due to poor compliance. Therefore, 172 Patients were randomized in group I (3 7.2 Gy) and the others were randomized in group II (4 6 Gy).
3 Comparison of Two HDR Schedules in Cervix 283 The total treatment time was 49 days in both groups. All data are shown in Table 1. a) Local control rate (p = 0.146) Treatment results With the median follow-up time of 35 months, local control, disease-free survival and overall survival rates were 80.8%, 63.4%, 98.8% in group I and 86.7%, 63.8%, 97.3% in group II, respectively. All data of both groups are shown in Table 2 and Fig. 1. Analysis was performed on stage IIB and stage IIIB which had the largest populations in these groups. In stage IIB, local control, disease-free survival and overall survival rates were not statistically significant between both groups. In stage IIIB, the tendency was the same except local control rates in stage IIIB (p = 0.065). All data of both groups are shown in Table 3 and Figs Toxicity profiles In the toxicity profiles, seven patients in group I developed acute grade 2 4 gastrointestinal toxicities and two patients in group II. In genitourinary toxicities, there were b) Disease-free survival rate (p = 0.971) Table 1. Patient characteristic data between two groups Parameters (3 7.2 Gy) N = 172 (4 6 Gy) N = 188 P-value Age 49 (30 69) 50 (31 69) Stage IIB IIIA 2 2 IIIB IVA 0 2 Histology SCCA ACA Others 5 7 Chemotherapy Cisplatin Mitomycin-C c) Overall survival rate (p = 0.336) Table 2. The three year local control rate, disease-free survival rate and overall survival rate between group I (3 7.2 Gy) versus group II (4 6 Gy) Parameters (N = 172) (N = 188) Local control rate 80.70% 86.10% Disease-free survival rate 67.60% 68.10% Overall survival rate 98.40% 96.70% Fig. 1. Kaplan-Meier curve showing a) local control rate b) diseasefree survival rate and c) overall survival rate of group I (blue line) versus group II (green line).
4 284 a) Local control rate in stage IIB (p = 0.763) E. Tharavichitkul et al. a) Local control rate in stage IIIB (p = 0.065) b) Disease-free survival rate in stage IIB (p = 0.525) b) Disease-free survival rate in stage IIIB (p = 0.327) c) Overall survival rate in stage IIB (p = 0.602) c) Overall survival rate in stage IIIB (p = 0.447) Fig. 2. Kaplan-Meier curve showing a) local control rate b) diseasefree survival rate and c) overall survival rate group I (blue line) versus group II (green line) in stage IIB of carcinoma of the cervix uteri. Fig. 3. Kaplan-Meier curve showing a) local control rate b) diseasefree survival rate and c) overall survival rate of group I (blue line) versus group II (green line) in stage IIIB of carcinoma of the cervix uteri.
5 Comparison of Two HDR Schedules in Cervix 285 Table 3. The three year local control rate, disease-free survival rate and overall survival rate of group I (3 7.2 Gy) versus group II (4 6 Gy) according to stage Stage IIB (N = 106) (N = 109) Local control rate 84.50% 87.60% Disease-free survival rate 73% 74.30% Overall survival rate 98.80% 97.90% Stage IIIB (N = 64) (N = 75) Local control rate 73% 82.20% Disease-free survival rate 58.80% 57.40% Overall survival rate 97.40% 94.50% Table 4. Acute toxicity of group I (3 7.2 Gy) versus group II (4 6 Gy) Acute toxicities (N = 172) (N = 188) GI toxicities grade % 46.30% grade % 1.10% 0.09 GU toxicities grade % 21.80% grade % 1.60% Table 5. Late toxicity profiles of group I (3 7.2 Gy) versus group II (4 6 Gy) Late toxicities (N = 172) (N = 188) GI toxicity grade % 10.10% grade % 2.70% GU toxicity grade % 5.30% grade % 0 three patients in group I and three patients in group II who developed grade 2 4 toxicities. No statistical significance could be observed in both GI (0.123) and GU (0.991) toxicities. In late toxicity, no patient in group I developed grade 3 4 GU toxicities while two patients in group II developed grade 3 4 GU toxicities. In GI toxicities, there were six and five patients in group I and group II, respectively, who developed grade 3 4 severity. All data are shown in Tables 4 and 5. DISCUSSION Intracavitary brachytherapy is one component of the radiotherapeutic treatment of carcinoma of cervix uteri. The dosage schedule of brachytherapy in cervical cancer is controversial. High-dose-rate brachytherapies are used worldwide due to the short treatment time, outpatient basis and better radiation protection for hospital staff. 16,17) The optimal fractionation schedules for HDR brachytherapy are still controversial. Orton et al. showed an increase of morbidity when the dose per fraction at point A was higher than 7 Gy. 18) Petereit et al. reported the results of HDR brachytherapy for cervix cancer using different regimens, however, this study failed to identify the optimal fractionation. 4) Consequently, the study of the fractionation schedule of HDR brachytherapy continues to have a lack of data support. A few studies tried to compare the effectiveness of the different schedules and the results revealed no statistical significance. From the study of Wong et al., the retrospective study reported the results of 7 Gy 3 fractions versus 6 Gy 4 fractions in 220 patients. They found that the two HDR fractionation schedules were not a significant prognosticator in the prediction of disease control and complications. 19) In the study from Korea by Nam et al., 46 patients were included in a comparison between 3 Gy 10 fractions (group A) versus 5 Gy 5 fractions (group B). The three year disease-specific survival rates of group A and B were 90.5% and 84.9%, respectively (p = 0.64). No difference of the three-year pelvic control was observed (p = 0.92). The incidences of late complications of the rectum or bladder of grade 2 or greater in group A and group B were 23.8% and 9.1%, respectively (p = 0.24). It showed comparable results between the both fractionation schedules. 20) In this study, the results of 7.2 Gy 3 fractions versus 6 Gy 4 fractions were comparable. No difference was observed in local control, disease-free survival and overall survival rates in group I versus group II. In stage IIB, local control, disease-free survival and overall survival rates between group I and group II were not statistically significant. In stage IIIB, no statistical significance in all parameters could be observed although there was an improvement of local control in group II (73% vs. 82.2%). In toxicity profiles, the grade 2 4 acute toxicities were equal between the two groups in terms of gastrointestinal toxicities and genitourinary toxicity aspects. In late toxicities, no statistical significance between the two groups in terms of grade 3 4 gastrointestinal toxicities and genitourinary toxicities was observed. The patient characteristics of both groups were not statistically significant in age, stage and histology. The median treatment time between group I and group II was 49 days which might be one of the factors. For the chemotherapy schedules (cisplatin vs. mitomycin- C), the analysis from our institution was published by
6 286 E. Tharavichitkul et al. Kamnerdsupaphon et al. At the median follow-up time of 17.5 months, the overall survival of these concurrent nonplatinum chemoradiation were not inferior to the standard cisplatin-based regimen (p = 0.19), although the disease-free survival showed a significant difference favoring the cisplatin arm (p = 0.006). 21) Our results showed that the acute side effects are tolerable in patients who are treated with concurrent chemoradiotherapy and late complications were similar. This study showed comparable results of the two fractionation schedules of high-dose-rate brachytherapy in carcinoma of cervix uteri. In stage IIIB, the dose of 4 6 Gy was better than the dose of Gy in terms of local control rates but not in disease-free survival and overall survival rates. For the BED 10, our study showed the BED 10 of 85.2 Gy 10 in group I and 86.4 Gy 10 in group II which related to the recommended dose of ABS. 5) When compared with the Japanese schedule (Nakano et al.) which showed the BED 10 of Gy 10 in locally advanced disease (stage II/ III), our BED 10 was higher. 22) In comparison with our routine schedule reported by Lorvidhaya in 2003, the BED 10 was around 87.6 to Gy 10. Although the BED 10 was high, the overall rate of Grades 3 and 4 RTOG complications was 4.2%. 23) Interestingly, the study for Toita et al. showed the cumulative BED Gy 10 at point A is appropriate for uterine cervical cancer patients treated with a combination of EBRT and HDR-ICBT. Moreover, the study reported patients who received treatment with 86.4 Gy 10 at point A suffered both proctitis and enterocolitis which equalled to the BED10 of our study in group II (4 6 Gy). 24) However, our study in this group showed only 2.7% of grade 3 4 GI late complications. In summary, our study showed that no statistical significance in terms of local control, disease-free survival, overall survival and complication rates between the two treatment schedules could be observed. The two HDR schedules seem to be safe and effective for the treatment of locally advanced cervical cancer. ACKNOWLEDGEMENTS The authors wish to thank Dr. Apichart Panichchewalak, Dr. Pimkhuan Kamnerdsupaphon and all staffs of The division of therapeutic radiology and oncology, faculty of medicine, Chinag Mai University for their initial findings which provided the foundation of this study. REFERENCES 1. Perez CA, et al (1986) Radiation therapy alone in the treatment of carcinoma of the uterine cervix: a 20-year experience. Gynecol Oncol 23: ICRU report 38 (1985) Dose and volume specification for reporting intracavitary therapy in gynecology. Bethesda, MD: International Commission on Radiation Units and Measurements: Ferrigno R, et al (2001) High-dose rate brachytherapy in the treatment of uterine cervix cancer. Analysis of dose effectiveness and late complications. Int J Radiat Oncol Biol Phys 50: Petereit DG and Pearcey R (1999) Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: Is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 43: Nag S, et al (2000) The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carinoma of the cervix. Int J Radiat Oncol Biol Phys 48: Toita T, et al (2009) Current status and perspectives of brachytherapy for cervical cancer. Int J Clin Oncol 14: Viani GA, et al (2009) Brachytherapy for cervix cancer: lowdose rate or high-dose rate brachytherapy-a meta-analysis of clinical trials. J Exp Clin Cancer Res 28: Whitney CW, et al (1999) A Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17: Morris M, et al (1999) Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for highrisk cervical cancer. N Engl J Med 340: Rose PG, et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340: National Cancer Institute (2003) Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0. DCTD, NCI, NIH, NHHH Miller AB, et al (1990) Reporting results of cancer treatment. Cancer 47: Cox JD, Stetz J and Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31: Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: Orton C (1991) HDR: forgot not time and distance. Int J Radiat Oncol Biol Phys 20: Speiser B (1991) Advantages of high dose rate remote afterloading systems: physics or biology. Int J Radiat Oncol Biol Phys 20: Orton CG, Seyedsadr M and Somnay A (1991) Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys 21: Wong F, et al (2003) Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens. Int J Radiat Oncol Biol Phys 55: Nam TK and Ahn SJ (2004) A prospective randomized study on two dose fractionation regimens of high-dose-rate brachytherapy for carcinoma of uterine cervix: comparison of effica-
7 Comparison of Two HDR Schedules in Cervix 287 cies and toxicities between two regimens. J Korean Med Sci 19: Kamnerdsupaphon P, et al (2008) Cisplatin vs. mitomycin in concurrent with radiotherapy for locally advanced cervical cancer. J Thai Soc Ther Radiol Oncol 14: Nakano, et al (2005) Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 103: Lorvidhaya, et al (2003) Concurrent mitomycin c, 5-fluorouricil, and radiotehrapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 55: Toita T, et al (2003) Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule. Int J Radiat Oncol Biol Phys 56: Received on March 8, 2011 Revision received on May 29, 2011 Accepted on June 2, 2011
High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible??
DOI 10.1007/s13224-015-0812-8 ORIGINAL ARTICLE High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible?? Saptarshi Ghosh 1 Pamidimukalabramhananda
More informationCombined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand
Tharavichitkul et al. BMC Cancer (2016) 16:501 DOI 10.1186/s12885-016-2558-9 RESEARCH ARTICLE Open Access Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution
More informationEvaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 In Carcinoma of Cervix
Iran J Cancer Preven. 2015 August; 8(4):e3573. Published online 2015 August 24. DOI: 10.17795/ijcp-3573 Research Article Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy
More informationUniversity Cooperation Platform
Starting a Brachytherapy Program in Government Controlled Healthcare Systems Razvan Galalae, MD, PhD Associate Professor, Medical Faculty, Christian Albrecht University Kiel, Germany, and Head of Radiotherapy
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org High Dose Rate Brachytherapy in Cervix Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationChapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.129 Research Paper Establishing
More informationINTRODUCTION PATIENT. J. Radiat. Res., 52, (2011)
J. Radiat. Res., 52, 54 58 (2011) Regular Paper Intracavitary Combined with CT-guided Interstitial Brachytherapy for Locally Advanced Uterine Cervical Cancer: Introduction of the Technique and a Case Presentation
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 5 MARCH 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationD. LONG, H. FRIEDRICH-NEL, L. GOEDHALS AND G. JOUBERT
HIGH DOSE-RATE BRACHYTHERAPY IN THE RADICAL TREATMENT OF CERVICAL CANCER. AN ANALYSIS OF DOSE EFFECTIVENESS AND INCIDENCE OF LATE RADIATION COMPLICATIONS D. LONG, H. FRIEDRICH-NEL, L. GOEDHALS AND G. JOUBERT
More informationhttps://patient.varian.com/sit es/default/files/videos/origin al/imrt.mp4 brachy- from Greek brakhys "short" Historically LDR has been used. Cs-137 at 0.4-0.8 Gy/h With optimally placed device, dose
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationOriginal Article ABSTRACT INTRODUCTION
Original Article Free full text available from www.cancerjournal.net Significance of ovoid separation with various applications of high-dose-rate-intracavitary radiotherapy in carcinoma of uterine cervix:
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationPrognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases
Original Article J Gynecol Oncol Vol. 24, No. 3:229-235 pissn 2005-0380 eissn 2005-0399 Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic
More informationThree fraction high dose rate brachytherapy schedule for treatment of locally advanced uterine cervix cancer center:
Huerta et al, Cancerología 3 (008): 105-110 Three fraction high dose rate brachytherapy schedule for treatment of locally advanced uterine cervix cancer center: Clinical results, emphasis in dosimetric
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationConcurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
Original Article J Gynecol Oncol Vol. 24, No. 2:108-113 http://dx.doi.org/10.3802/jgo.2013.24.2.108 pissn 2005-0380 eissn 2005-0399 Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk
More informationICRT รศ.พญ.เยาวล กษณ ชาญศ ลป
ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป Brachytherapy การร กษาด วยร งส ระยะใกล Insertion การสอดใส แร Implantation การฝ งแร Surface application การวางแร physical benefit of brachytherapy - very high dose of radiation
More informationCOX-2 inhibitor and irradiation. Saitama Cancer Center Kunihiko Kobayashi MD, PhD
COX-2 inhibitor and irradiation Saitama Cancer Center Kunihiko Kobayashi MD, PhD Synthesis of prostaglandins from arachidonic acid by cyclooxygenase (COX) enzymes JNCI 95:1440, 2003 Difference between
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationComparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer
Comparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer Poster No.: RO-0049 Congress: RANZCR FRO 202 Type: Authors: Scientific Exhibit G. Govindarajulu, A.
More informationLong Term Outcome after Concurrent Chemo radiation with Cisplatin in Carcinoma Cervix
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i10.03 Long Term Outcome after Concurrent Chemo
More informationKEY WORDS: Carcinoma cervix, high-dose-rate brachytherapy, radiotherapy
Technical Report Free full text available from www.cancerjournal.net Vandana S Jain, Mukund B Sarje, Kailash K Singh, R Umberkar, Rajeev Shrivastava, Shailendra M Jain Department of Radiotherapy and Clinical
More informationEducational Activity. Review paper. Abstract
Review paper Educational Activity University Cooperation Platform (UCP) between Christian-Albrechts-University Kiel (Germany) and Chiang Mai University (Thailand): implementation of image-guided gynecological
More informationEditorial Process: Submission:09/12/2017 Acceptance:06/19/2018
DOI:10.22034/APJCP.2018.19.10.2745 Concurrent Chemo-Radiobrachytherapy in Cervical Cancer RESEARCH ARTICLE Editorial Process: Submission:09/12/2017 Acceptance:06/19/2018 Concurrent Chemo- Radiobrachytherapy
More informationThe role of esophageal brachytherapy
Esophageal cancer is combination with surgery (stents) or EBRT a better solution? Razvan Galalae, MD, PhD Associate Professor, Medical Faculty, Christian Albrecht University Kiel, Germany, and Head of
More informationHypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
More informationRadiobiological quality of high dose rate interstitial brachytherapy treatments of carcinoma of the cervix
Rep Pract Oncol Radiother, 6; 11(1): 13-22 Original Paper Received: 3.12.2 Accepted: 6.1.25 Published: 6.2.27 Authors Contribution: A Study Design B Data Collection C Statistical Analysis D Data Interpretation
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationDefinitions. Brachytherapy in treatment of cancer. Implantation Techniques and Methods of Dose Specifications. Importance of Brachytherapy in GYN
Implantation Techniques and Methods of Dose Specifications Brachytherapy Course Lecture V Krishna Reddy, MD, PhD Assistant Professor, Radiation Oncology Brachytherapy in treatment of cancer GYN Cervical
More informationConcurrent chemoradiation in treatment of carcinoma cervix
N. J. Obstet. Gynaecol Vol. 2, No. 1, p. 4-8 May -June 2007 REVIEW Concurrent chemoradiation in treatment of carcinoma cervix Meeta Singh, Rajshree Jha, Josie Baral, Suniti Rawal Dept of Obs/Gyn, TU Teaching
More informationINTRODUCTION. Taek Keun Nam, Sung Ja Ahn
J Korean Med Sci 2004; 19: 87-94 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences A Prospective Randomized Study on Two Dose Fractionation Regimens of High-Dose-Rate Brachytherapy for Carcinoma
More informationInterstitial Brachytherapy. Low dose rate brachytherapy. Brachytherapy alone cures some cervical cancer. Learning Objectives
Interstitial Learning Objectives To discuss practical aspects of selection and insertion techniques for interstitial brachytherapy and their relation to clinical trials Akila Viswanathan, MD MPH Johns
More informationGYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology
GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial
More informationPelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
More informationORIGINAL ARTICLE. Summary. Introduction
Journal of BUON 17: 740-745, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Cisplatin monotherapy with concurrent radiotherapy versus combination of cisplatin and 5-fluorouracil
More informationEarly clinical outcomes of 3D-conformal radiotherapy using. accelerated hyperfractionation without intracavitary brachytherapy
K. Matsuura, et al 1 Early clinical outcomes of 3D-conformal radiotherapy using accelerated hyperfractionation without intracavitary brachytherapy for cervical cancer K. Matsuura, M.D., Ph.D., a,b H. Tanimoto,
More informationWeekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer
REVIEW ARTICLE Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer A Meta-Analysis Xingxing Chen, MD,* Haizhou Zou, MD,Þ Huifang Li, MD,*
More informationCarbon-ion radiotherapy for marginal lymph node recurrences of cervical cancer after definitive radiotherapy: a case report
Tamaki et al. Radiation Oncology 2013, 8:79 CASE REPORT Open Access Carbon-ion radiotherapy for marginal lymph node recurrences of cervical cancer after definitive radiotherapy: a case report Tomoaki Tamaki
More informationRadical Radiotherapy for Locally Advanced Cancer of U terine Cervix
Cancer Research and Treatment 2004;36(4):222-227 Radical Radiotherapy for Locally Advanced Cancer of U terine Cervix Jeung Eun Lee, M.D. 1, Seung Jae Huh, M.D. 1, Won Park, M.D. 1, Do Hoon Lim, M.D. 1,
More informationMETHODS. Study population. Treatment schedule
British Journal of Cancer (2007) 97, 1058 1062 All rights reserved 0007 0920/07 $30.00 www.bjcancer.com Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationThe Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy
The Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy Suisui Song, MD 1 ; Sonali Rudra, MD 1 ; Michael D. Hasselle, MD 2 ; Paige L. Dorn, MD 1 ; Loren
More informationComparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail
Comparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail Dr. Nishee Srivastava MD, Dr. Kamal Sahani MD, Dr. Manoj
More informationConcurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer
Med. J. Cairo Univ., Vol. 82, No. 2, March: 351-357, 2014 www.medicaljournalofcairouniversity.net Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationfor the Degree of Master of Medicine in Radiation oncology WONDEMAGEGNHU TIGENEH MB. Ch. B, FCR (Onc) SA. Division of Radiation Oncology
A Prospective Randomized Study Comparing Three-Fraction Regimens of HDR Brachytherapy with concomitant chemo-radiotherapy for Cancer of the Cervix Stage IIB and IIIB A thesis submitted to the faculty of
More informationOriginal Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September Implementation Date: December 2014 Clinical Operations
National Imaging Associates, Inc. Clinical guideline CERVICAL CANCER Original Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September 2014 Guideline Number: NIA_CG_223 Last Revised Date:
More informationchemoradiation. Each of these trials had slightly different interventions,
Research ONCOLOGY Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial Frederick B. Stehman, MD; Shamshad Ali, MS, MStat;
More informationNordic Society for Gynecological Oncology Advisory Board of Radiotherapy
Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Guidelines for postoperative irradiation of cervical cancer Contents: 1. Treatment planning for EBRT. 2 2. Target definition for
More informationPatterns of Care in Patients with Cervical Cancer:
Patterns of Care in Patients with Cervical Cancer: Power and Pitfalls of Claims-Based Analysis Grace Smith, MD, PhD, MPH Resident, PGY-5 Department of Radiation Oncology, MD Anderson Cancer Center Acknowledgments
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 340 A PRIL 15, 1999 NUMBER 15 PELVIC RADIATION WITH CONCURRENT CHEMOTHERAPY COMPARED WITH PELVIC AND PARA-AORTIC
More informationAbscopal Effect of Radiation on Toruliform Para-aortic Lymph Node Metastases of Advanced Uterine Cervical Carcinoma A Case Report
Abscopal Effect of Radiation on Toruliform Para-aortic Lymph Node Metastases of Advanced Uterine Cervical Carcinoma A Case Report MAMIKO TAKAYA 1, YUZURU NIIBE 1, SHINPEI TSUNODA 2, TOSHIKO JOBO 2, MANAMI
More informationOutcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_
bs_bs_banner doi:10.1111/j.1447-0756.2012.01871.x J. Obstet. Gynaecol. Res. Vol. 38, No. 11: 1315 1320, November 2012 Outcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_1871
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationCase Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
More informationQuimio Radioterapia en Cancer de Cervix
Quimio Radioterapia en Cancer de Cervix HIGINIA R. CÁRDENES PROFESSOR RADIATION ONCOLOGY CLINICAL DIRECTOR SCHNECK CANCER CENTER Worldwide incidence of cervical cancer 2014, 12.360 cases Global incidence
More information3D ANATOMY-BASED PLANNING OPTIMIZATION FOR HDR BRACHYTHERAPY OF CERVIX CANCER
SAUDI JOURNAL OF OBSTETRICS AND GYNECOLOGY VOLUME 11 NO. 2 1430 H - 2009 G 3D ANATOMY-BASED PLANNING OPTIMIZATION FOR HDR BRACHYTHERAPY OF CERVIX CANCER DR YASIR BAHADUR 1, DR CAMELIA CONSTANTINESCU 2,
More informationDose-Volume Histogram Analysis in Point A-based Dose Prescription of High-dose-rate Brachytherapy for Cervical Carcinoma
Showa Univ J Med Sci 30 2, 227 235, June 2018 Original Dose-Volume Histogram Analysis in Point A-based Dose Prescription of High-dose-rate Brachytherapy for Cervical Carcinoma Rei KOBAYASHI 1, Yoshikazu
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationRe: Comprehensive Ambulatory Payment Classification Methodology
Tiffany Swygert Director, Division of Outpatient Care Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244-1850 Re: Comprehensive Ambulatory Classification Methodology
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationManagement of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.
Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
More informationMedicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services US Department of Health and Human Services Attention: CMS-1695-FC P.O. Box 8013, 7500 Security Boulevard Baltimore, MD 21244-1850
More informationA Study on Dosimetry of Gynaecological Cancer and Quality Assurance of HDR Brachytherapy in BPKMCH, Nepal
A Study on Dosimetry of Gynaecological Cancer and Quality Assurance of HDR Brachytherapy in BPKMCH, Nepal SB Chand, PP Chaursia, MP Adhikary, AK Jha, and S Shrestha Dept. of Radiation Oncology, BPKM Cancer
More informationA SIMPLE METHOD OF OBTAINING EQUIVALENT DOSES FOR USE IN HDR BRACHYTHERAPY
PII S0360-3016(99)00330-2 Int. J. Radiation Oncology Biol. Phys., Vol. 46, No. 2, pp. 507 513, 2000 Copyright 2000 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/00/$ see front
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationAOGS MAIN RESEARCH ARTICLE
A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/ adenosquamous carcinoma and squamous
More informationThe effect of treatment prolongation in treatment of cervical cancer patient treated patients at rural center in India
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 9, Issue 2 (Jul.- Aug. 2013), PP 70-75 The effect of treatment prolongation in treatment of cervical
More informationImage based Brachytherapy- HDR applications in Gynecological Tumors
Image based Brachytherapy- HDR applications in Gynecological Tumors Yakov Pipman, D. Sc. North Shore LIJ Health System Sites amenable to treatment with HDR Brachytherapy GYN Breast Prostate Head and Neck
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationUvA-DARE (Digital Academic Repository) Prognostic factors in cervical cancer Biewenga, Petra. Link to publication
UvA-DARE (Digital Academic Repository) Prognostic factors in cervical cancer Biewenga, Petra Link to publication Citation for published version (APA): Biewenga, P. (2015). Prognostic factors in cervical
More informationIntraoperative Radiation Therapy for
Frontiers ofradiation Therapy and Oncology Reprint Editors: J.M. Vaeth, J.L. Meyer, San Francisco, Calif. ~' Publishers: S.Karger, Basel Printed in Switzerland Vaeth JM, Meyer JL (eds): The Role of High
More informationIsolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix
J Nepal Health Res Counc 2009 Oct;7(15):103-7 Original Article Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix Ghimire S 1, Hamid S, 2 Rashid A 2 1 Bhaktapur Cancer Hospital, Bhaktapur,
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationThe Evolution of RT Techniques for Gynaecological Cancers in a developing country context
The Evolution of RT Techniques for Gynaecological Cancers in a developing country context Hannah Simonds Stellenbosch University/ Tygerberg Academic Hospital ESMO Africa 2017 I have no disclosures External
More informationPostoperative Radiotherapy for Patients with Invasive Cervical Cancer Following Treatment with Simple Hysterectomy
Jpn J Clin Oncol 2003;33(9)477 481 Postoperative Radiotherapy for Patients with Invasive Cervical Cancer Following Treatment with Simple Hysterectomy Shang-Wen Chen 1,2, Ji-An Liang 1,2, Shih-Neng Yang
More informationHYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee
HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix
More informationHigh dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
Romano et al. Radiation Oncology (2018) 13:129 https://doi.org/10.1186/s13014-018-1074-2 RESEARCH Open Access High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of
More informationRecent Advances and current status of radiotherapy for cervix cancer
Recent Advances and current status of radiotherapy for cervix cancer Richard Pötter MD Department of Radiation Oncology, Medical University of Vienna, Austria ICARO-2, IAEA, Vienna, June, 24, 2017 Recent
More informationProspective comparative study of dose dense neo-adjuvant chemotherapy followed by chemo-radiation and definitive chemoradiation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Karpurmath SV et al. Int J Reprod Contracept Obstet Gynecol. 2016 Sept;5(9):2909-2914 www.ijrcog.org pissn 2320-1770 eissn
More informationRole of Twice Weekly HDR- Brachytherapy in Management of Carcinoma Of Uterine Cervix-Experience of Rural Centre in India
Global Journal of Medical research Interdsciplinary Volume 13 Issue 4 Version 1.0 Year 2013 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online
More informationEui-Sok Sol 1, Tae Sung Lee 1, Suk Bong Koh 1, Hun Kyu Oh 2, Gi Won Ye 3, Youn Seok Choi 1 INTRODUCTION
J Gynecol Oncol Vol. 20, No. 1:28-34, March 2009 DOI:10.3802/jgo.2009.20.1.28 Original Article Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel
More informationRadiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement
Original Article J Gynecol Oncol Vol. 23, No. 3:159-167 pissn 2005-0380 eissn 2005-0399 Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement
More informationBASIC CLINICAL RADIOBIOLOGY
INT6062: Strengthening Capacity for Cervical Cancer Control through Improvement of Diagnosis and Treatment BASIC CLINICAL RADIOBIOLOGY Alfredo Polo MD, PhD Applied Radiation Biology and Radiotherapy Section
More informationBrachytherapy an Overview
Brachytherapy an Overview Yakov Pipman, D Sc North Shore LIJ Health System Monterrey, Nov30-Dec1, 2007 Brachytherapy A procedure in therapeutic radiology that involves the irradiation of a target with
More informationVenezia Advanced Gynecological Applicator Reaching beyond
Venezia Advanced Gynecological Applicator Reaching beyond Advanced Gynecological Applicator Venezia is FDA cleared and CE marked, but is not available in all markets. 1 Helping clinicians improve patients
More informationPragyat Thakur 1,2, Rajeev Seam 1, Manoj Gupta 1, Manish Gupta 1. Introduction
Original Article on Newer Agents to Enhance Radiotherapeutic Outcomes Page 1 of 8 Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly
More informationHigh Versus Low Dose Rate Intracavitary Irradiation for Adenocarcinoma of the Uterine Cervix
Jpn J Clin Oncol 2001;31(9)432 437 High Versus Low Dose Rate Intracavitary Irradiation for Adenocarcinoma of the Uterine Cervix Woo Chul Kim 1, Gwi Eon Kim 2,ChangOkSuh 2 andjohnj.k.loh 1 1 Department
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationOriginal Article. Introduction. Soyi Lim 1, Seok-Ho Lee 2, Kwang Beom Lee 1, Chan-Yong Park 1
Original Article Obstet Gynecol Sci 2016;59(3):184-191 http://dx.doi.org/10.5468/ogs.2016.59.3.184 pissn 2287-8572 eissn 2287-8580 The influence of number of high risk factors on clinical outcomes in patients
More informationBrachytherapy Planning and Quality Assurance
Brachytherapy Planning and Quality Assurance Classical implant systems Most common clinical applications and modern dosimetry methods Quality assurance Classical implant systems Manchester (Paterson-Parker)
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationEfficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer
original studies Efficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer Nemes Adina 1, Nagy Viorica 1, 2, Todor Nicolae 1, Marita Andreea 1,
More information